Venous thromboembolism is a complication causing increased bleeding which occurs after an orthopedic surgery procedure. Professor Clifford W. Colwell has reported in the Journal of Arthroplasty that by giving a dose of ARIXTRA drug to these patients who underwent orthopedic surgery the complications and amount of bleeding decreased.
ARIXTRA drug which is called as FLEXTRA (Flexibility in Administration of Fondaparinux for Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery) is found to have anti-thrombotic activity which helps in coagulation by increasing the coagulating factors is found to be very useful in these patients and the drug is administered in the morning the day after surgery when the risk of developing venous thromboembolism is high.
The drug ARIXTRA is manufactured by the pharmaceutical giant GlaxoSmithKline and is found to inhibit the factor Xa protein which is present in the coagulation cascade pathway and the drug is found to effectively control venous thromboembolism and pulmonary embolism in patients who underwent bone surgery for knee and hip replacement. The drug ARIXTRA is found to have very less side effects of causing bleeding, bacterial endocarditis and hypersensitivity but the benefits of the drug is more beneficial than its side effect.